Lupin receives tentative approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Global pharma major Lupin Limited (Lupin) has received tentative approval from the United States Food and Drug Administration (U.S. FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets. This product would be manufactured at Lupin's Nagpur facility in India.

Commenting on the same, Mr. Naresh Gupta, President - API and Global Institution Business, Lupin said, "At Lupin, we are unwavering in our commitment to providing affordable and quality treatment options for patients in low and middle-income countries. We are pleased to receive the U.S. FDA's tentative approval of Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets, which significantly bolsters our HIV portfolio."

Shares of Lupin Limited was last trading in BSE at Rs. 934.85 as compared to the previous close of Rs. 945.75. The total number of shares traded during the day was 18668 in over 1098 trades.

The stock hit an intraday high of Rs. 947.95 and intraday low of 932.85. The net turnover during the day was Rs. 17552441.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals TentativeApproval USFDA DolutegravirLamivudine TenofovirAlafenamide Tablets PEPFAR